

5-Amino-6-chloro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl} quinoline-8-carboxamide hydrochloride;
 5-Amino-6-chloro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl} quinoline-8-carboxamide fumarate;
 5-Amino-6-chloro-*N*-{[3-(2-hydroxy-2-methyl propyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl} quinoline-8-carboxamide L(+)-tartarate;
 5-Amino-6-fluoro-*N*-{[1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl} quinoline-8-carboxamide L(+)-tartarate;
 5-Amino-6-fluoro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl} quinoline-8-carboxamide;
 5-Amino-6-fluoro-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl} quinoline-8-carboxamide L(+)-tartarate;
 5-Amino-6-bromo-*N*-{[1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl} quinoline-8-carboxamide L(+)-tartarate; and
 5-Amino-6-bromo-*N*-{[4-fluoro-1-(2-hydroxy-2-methyl propyl)-4-piperidinyl]methyl} quinoline-8-carboxamide L(+)-tartarate.

5. A pharmaceutical composition comprising a compound according to any one of the claims 1 to 4 and pharmaceutically acceptable excipients.

6. The pharmaceutical composition according to claim 5, for use in the treatment of clinical conditions mediated through 5-HT₄ receptor agonists such as Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression, psychiatric disorders, pain or gastrointestinal disorders.

7. The use of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of ~~A method of treating~~ Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression, psychiatric disorders, pain or gastrointestinal disorders, comprising administering to a patient in need thereof an effective amount of a said compound or pharmaceutically acceptable salt thereof ~~according to any one of claims 1 to 4.~~

8. Use of a compound according to any one of the claims 1 to 4 in the manufacture of a medicament for the treatment of diseases related to 5-HT₄ receptor agonists.

9. The use of compound according to the claim 8, in the manufacture of a medicament for the treatment of clinical conditions such as Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder, Huntington's disease, Parkinson's disease, depression, psychiatric disorders, pain or gastrointestinal disorders.